The Shotlee Journal
Browse Shotlee articles about Ozempic.
Showing 9 / 1086 Ozempic articles
Bollywood actress Bhumi Pednekar lost 40kg without Ozempic or injectables, despite constant rumors. She attributes her transformation to disciplined workouts, a balanced vegetarian diet, and recovery from severe dengue. Discover her practical tips for real weight management.
Viking Therapeutics stock closed at $34.34, up 11.44%, fueled by VK2735 Phase 2 success. The trial delivered 14.7% average weight reduction, challenging GLP-1 leaders like Ozempic. Acquisition speculation boosts investor interest.
Weight loss drugs like GLP-1 medications are transforming consumer spending patterns. New Circana research reveals users cut grocery costs by 2% but increase outlays on beauty and self-care items. Protein-focused products surge 40% as users combat muscle loss side effects.
Hims & Hers investment narrative shifts amid legal scrutiny on compounded GLP-1 agonists. A January 2026 antitrust lawsuit accuses Eli Lilly and Novo Nordisk of blocking compounded Mounjaro and Wegovy. This raises uncertainties for telehealth providers reliant on these affordable weight management options.
GLP-1 medications are revolutionizing not just weight loss but how people approach food, prioritizing protein quality over quantity. Research shows users eat less overall, including less meat, yet value nutrient-dense proteins more highly. These changes signal premiumization in the food sector and broader economic impacts. (~198 chars)
A registered nurse in Chicago is under federal charges for handing out counterfeit versions of the weight-loss medication Ozempic. The drugs, which did not contain the key component semaglutide, were allegedly distributed to three people. She has pleaded not guilty and faces potential jail time.
An analysis of public data shows that pharmaceutical firms paid over $533,000 to Indiana healthcare professionals in 2024 for speaking about GLP-1 medications. The funds covered travel and expenses for conferences. Experts discuss potential influences on prescribing practices, while doctors defend the educational value.
The Food and Drug Administration announced on Tuesday its desire to remove suicide warning labels from GLP-1 weight-loss medications. A comprehensive review of 91 trials revealed no heightened risk of suicidal thoughts or behaviors among users compared to placebo groups. This change aligns the labels with those of diabetes equivalents from the same manufacturers.
Wall Street experts highlight unexpected benefits for airlines from GLP-1 medications like Ozempic, including significant fuel cost reductions due to lighter travelers. Analysts predict that widespread adoption could lead to billions in savings by reducing aircraft weight. This trend intersects pharmaceutical advancements with aviation economics.
